312 related articles for article (PubMed ID: 21894173)
1. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.
Wilson NS; Yang B; Morelli AB; Koernig S; Yang A; Loeser S; Airey D; Provan L; Hass P; Braley H; Couto S; Drane D; Boyle J; Belz GT; Ashkenazi A; Maraskovsky E
Immunol Cell Biol; 2012 May; 90(5):540-52. PubMed ID: 21894173
[TBL] [Abstract][Full Text] [Related]
2. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
3. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
[TBL] [Abstract][Full Text] [Related]
4. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.
Schnurr M; Orban M; Robson NC; Shin A; Braley H; Airey D; Cebon J; Maraskovsky E; Endres S
J Immunol; 2009 Feb; 182(3):1253-9. PubMed ID: 19155470
[TBL] [Abstract][Full Text] [Related]
5. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
Robson NC; McAlpine T; Knights AJ; Schnurr M; Shin A; Chen W; Maraskovsky E; Cebon J
Blood; 2010 Jul; 116(2):218-25. PubMed ID: 20430956
[TBL] [Abstract][Full Text] [Related]
6. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo.
Silva A; Mount A; Krstevska K; Pejoski D; Hardy MP; Owczarek C; Scotney P; Maraskovsky E; Baz Morelli A
J Immunol; 2015 Mar; 194(5):2199-207. PubMed ID: 25646304
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer.
Barr AM; Silva A; Prato S; Belz GT; Maraskovsky E; Baz Morelli A
Cancer Immunol Immunother; 2020 Oct; 69(10):1959-1972. PubMed ID: 32388678
[TBL] [Abstract][Full Text] [Related]
8. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
Drane D; Gittleson C; Boyle J; Maraskovsky E
Expert Rev Vaccines; 2007 Oct; 6(5):761-72. PubMed ID: 17931156
[TBL] [Abstract][Full Text] [Related]
9. Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant.
Wilson NS; Duewell P; Yang B; Li Y; Marsters S; Koernig S; Latz E; Maraskovsky E; Morelli AB; Schnurr M; Ashkenazi A
J Immunol; 2014 Apr; 192(7):3259-68. PubMed ID: 24610009
[TBL] [Abstract][Full Text] [Related]
10. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases.
Baz Morelli A; Becher D; Koernig S; Silva A; Drane D; Maraskovsky E
J Med Microbiol; 2012 Jul; 61(Pt 7):935-943. PubMed ID: 22442293
[TBL] [Abstract][Full Text] [Related]
11. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Cebon JS; Gore M; Thompson JF; Davis ID; McArthur GA; Walpole E; Smithers M; Cerundolo V; Dunbar PR; MacGregor D; Fisher C; Millward M; Nathan P; Findlay MPN; Hersey P; Evans TRJ; Ottensmeier CH; Marsden J; Dalgleish AG; Corrie PG; Maria M; Brimble M; Williams G; Winkler S; Jackson HM; Endo-Munoz L; Tutuka CSA; Venhaus R; Old LJ; Haack D; Maraskovsky E; Behren A; Chen W
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317292
[TBL] [Abstract][Full Text] [Related]
12. ISCOMs and ISCOMATRIX.
Sun HX; Xie Y; Ye YP
Vaccine; 2009 Jul; 27(33):4388-401. PubMed ID: 19450632
[TBL] [Abstract][Full Text] [Related]
13. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8
Matsuo K; Kitahata K; Kawabata F; Kamei M; Hara Y; Takamura S; Oiso N; Kawada A; Yoshie O; Nakayama T
Front Immunol; 2018; 9():2775. PubMed ID: 30542351
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
[TBL] [Abstract][Full Text] [Related]
15. MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity.
Collinson-Pautz MR; Slawin KM; Levitt JM; Spencer DM
PLoS One; 2016; 11(10):e0164547. PubMed ID: 27741278
[TBL] [Abstract][Full Text] [Related]
16. CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses.
McCluskie MJ; Weeratna RD; Evans DM; Makinen S; Drane D; Davis HL
Biomed Res Int; 2013; 2013():636847. PubMed ID: 23586050
[TBL] [Abstract][Full Text] [Related]
17. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
18. ISCOMATRIX adjuvant for antigen delivery.
Pearse MJ; Drane D
Adv Drug Deliv Rev; 2005 Jan; 57(3):465-74. PubMed ID: 15560952
[TBL] [Abstract][Full Text] [Related]
19. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers.
Drane D; Maraskovsky E; Gibson R; Mitchell S; Barnden M; Moskwa A; Shaw D; Gervase B; Coates S; Houghton M; Basser R
Hum Vaccin; 2009 Mar; 5(3):151-7. PubMed ID: 19246990
[TBL] [Abstract][Full Text] [Related]
20. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy.
Narayanan P; Lapteva N; Seethammagari M; Levitt JM; Slawin KM; Spencer DM
J Clin Invest; 2011 Apr; 121(4):1524-34. PubMed ID: 21383499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
